Search our extensive Laboratory Test Directory to find test codes, ordering recommendations, specimen stability information, Test Fact Sheets, and more.
Recommendations when to order or not order the test. May include related or preferred tests.
Consider ordering in individuals with stiff-person syndrome, paraneoplastic encephalomyelitis (PEM), and sensory neuronopathy (SN). May aid in diagnosis of occult tumor, recurrence of tumor, or second tumor. Serum is the preferred specimen; see Amphiphysin Antibody, IgG (2008893).
New York DOH Approval Status
Indicates test has been approved by the New York State Department of Health.
This test is New York state approved.
Specimen Required
Patient PreparationInstructions patient must follow before/during specimen collection.
CollectSpecimen type to collect. May include collection media, tubes, kits, etc.
CSF.
Specimen PreparationInstructions for specimen prep before/after collection and prior to transport.
Transfer 1mL CSF to an ARUP Standard Transport Tube. (Min: 0.60 mL)
Storage/Transport TemperaturePreferred temperatures for storage prior to and during shipping to ARUP. See Stability for additional info.
Refrigerated.
Unacceptable ConditionsCommon conditions under which a specimen will be rejected.
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
RemarksAdditional specimen collection, transport, or test submission information.
StabilityAcceptable times/temperatures for specimens. Times include storage and transport time to ARUP.
Expected turnaround time for a result, beginning when ARUP has received the specimen.
1-4 days
Reference Interval
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Negative
Interpretive Data
May include disease information, patient result explanation, recommendations, or details of testing.
Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small cell lung cancer and breast tumors.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Compliance Category
Laboratory Developed Test (LDT)
Note
Additional information related to the test.
Hotline History
N/A
CPT Codes
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Connect Sign In
